NewsSource: EClinCloud

Understanding the Differences Between Research and Clinical Visual Acuity Charts

7 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration

In everyday life, visual acuity charts are familiar to everyone. You often hear—

Article illustration
Article illustration

"My vision is 0.8; what is yours?"

During an eye exam at a hospital or a physical checkup, a doctor will also point to an eye chart and ask you—

"Can you see this line? Which one is clearer?"

Article illustration
Article illustration
Visual acuity charts are the most commonly used examination tool in ophthalmology and serve as the standard for quantifying visual acuity. From a clinical research perspective, a patient's ocular condition and treatment effect are reflected through visual acuity charts.
Article illustration
What are the differences between visual acuity charts used in research and those used in clinical practice?
What is the international gold standard for vision research?
Let's take a closer look


Article illustration

Quick question: what visual acuity charts are commonly used today?

Outside China, the most commonly used charts in clinical practice are the Snellen chart and the Landolt C chart, whereas in China, the most commonly used charts in clinical practice are the International Standard Visual Acuity Chart and the Standard Logarithmic Visual Acuity Chart.

Article illustration

Article illustration

Commonly used visual acuity charts1

Because both the Snellen chart and the International Standard Visual Acuity Chart have several limitations—such as uneven progression of optotype sizes, differing legibility among optotypes, and varying numbers of letters per line—Bailey and Lovie modified the Snellen chart in 1976 to create the Bailey-Lovie chart.
Article illustration

Snellen Chart                                       Bailey-Lovie Chart

Image source: Precision Vision

In 1982, Ferris further refined the Bailey-Lovie chart for use in the ETDRS study; known as the ETDRS chart, it became the international gold standard for vision research, and in recent years it has also gained increasing attention in clinical practice and research in China2.

So the ETDRS chart is the international gold standard for vision research.

Article illustration
ETDRS stands for the Early Treatment Diabetic Retinopathy Study, which was initiated and sponsored by the National Eye Institute (NEI); the ETDRS chart was the visual acuity chart developed in that study.

It is primarily used to assess changes in visual acuity following treatment in patients with diabetic retinopathy, and can also be used to assess visual acuity in patients with other ophthalmic diseases such as age-related macular degeneration.

So what distinguishes the ETDRS chart from other visual acuity charts?

Design principles and characteristics of the ETDRS visual acuity chart3:
(1) Equal optotype legibility: Each row of the ETDRS chart consists of 5 Sloan letters of equal size and reading difficulty, with 14 rows in total;
(2) Constant optotype progression rate: The letter size in each row is 0.7943 times that of the row above, halving every three rows (0.79433=0.5);
(3) Uniform optotype spacing: The spacing between letters within a row equals the letter size of that row, and the spacing between two adjacent rows equals the letter size of the lower row.
Article illustration

ETDRS Chart 1                     ETDRS Chart 2                    ETDRS Chart R

Image source: I-SEE.org

What are the advantages of the ETDRS chart?



01


More effective for low-vision testing

This is because the ETDRS chart can be used at variable testing distances.

When letters cannot be read at 4 meters, the testing distance can be moved to 2 meters or even 1 meter;

At 4 meters, an optotype on row n (n ≤ 11) subtends the same visual angle at the human eye as an optotype on row (n + 3) at 2 meters;

At 4 meters, an optotype on row n (n ≤ 8) subtends the same visual angle at the human eye as an optotype on row (n + 6) at 1 meter.

Article illustration
This means that visual acuity results obtained under very low vision can be quantified (i.e., the number of letters read), sharing the same property—homogeneity—as measurements obtained in high or moderate vision, so that after conversion the results can be applied equally in clinical statistics2.

In contrast, the spacing between letters and between rows on the Snellen chart is not standardized. When letters are arranged too closely together, a crowding phenomenon occurs, causing measured visual acuity to be lower than true visual acuity. In addition, the Snellen chart records visual acuity in decimal notation, making the results difficult to convert into logarithmic visual acuity and difficult to use in clinical statistics3. Studies have shown that in the same population, visual acuity test results with the ETDRS chart are better than those with the Snellen chart, especially evident in low-vision testing3.



02

Better repeatability

There is also a substantial difference in repeatability between the ETDRS chart and the Snellen chart, with the former showing better repeatability than the latter. The reported 95% confidence interval (CI) for the coefficient of repeatability (CR) of the ETDRS chart is 0.07–0.16 logMAR (3.5–8 letters) in a normal population, and its CR 95% CI is 0.2–0.3 logMAR (10–15 letters) in a visually impaired population3; whereas the Snellen chart has a large repeated-measurement variability, ranging from 5 to 16.5 letters in a normal population and up to 3.3 lines in patients with ophthalmic disease; such variability is unacceptable for scientific research2.



03

Wider spacing between adjacent letters within a row

The Bailey-Lovie and ETDRS charts share the same design principles, with 5 letters per size level, size increments of exactly 0.10 log units, and standardized spacing between letters and rows. The differences between them are the standard testing distance (6 meters and 4 meters, respectively, with the ETDRS chart also usable at variable distances) and the optotype letter set (1968 British Standard letters vs. Sloan letters, respectively). This choice of letters means that the ETDRS chart has wider spacing between adjacent letters within a row (5 units vs. 4 units)4.

Many new charts were subsequently developed based on the design principles of the Bailey-Lovie and ETDRS charts and the logMAR visual acuity scoring method, incorporating existing optotypes such as Tumbling E and Landolt C as well as other optotypes such as various numbers, picture symbols, and letters and characters from other alphabets4.
Article illustration

With this brief introduction, you now have an overview of visual acuity charts. As a measurement and assessment tool commonly used in clinical practice, scales are essential for assessing disease severity and supporting objective diagnosis and treatment.


Driven by science and medicine, EClinCloud has built an end-to-end, interconnected, integrated digital clinical trial cloud platform, providing clinical trial endpoint assessment solutions across therapeutic areas (including central nervous system, ophthalmology, and others).

We not only have an extensive scale library, but also an experienced team of experts providing one-stop scale services to help clients resolve scale-related issues in clinical trials faster and better.
Feel free to contact us anytime.

References

1. Cao Suqi, Zhao Yukai, Hou Fang, et al. History, current status, and development trends of visual acuity charts. Chinese Journal of Optometry Ophthalmology and Visual Science, 2021, 23(10):7.

2. Wang Shuang, Liu Yang, Liu Nan, Zhao Jinsong. ETDRS visual acuity chart and its application in age-related macular degeneration. Chinese Journal of Gerontology, 2015,0(17):5008-5010.

3. Tan Qi, Liu Longqian. Principles and use of the ETDRS chart and its comparison with the Snellen chart. Chinese Journal of Optometry Ophthalmology and Visual Science, 2013,15(10):633-636.

4. Bailey IL, Lovie-Kitchin JE. Visual acuity testing. From the laboratory to the clinic. Vision Res. 2013 Sep 20;90:2-9.



About EClinCloud

EClinCloud is a technology company focused on clinical R&D that provides an integrated, interconnected clinical trial cloud platform (spanning technology products and solutions such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, and offering solutions including scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system, ophthalmology, and others). By combining cutting-edge technology with life-science data, EClinCloud is building a globally leading, patient-centric SaaS cloud platform supporting clinical evidence, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




Article illustration

Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.